Lot BP-35677 Save $22.50 BPC-157 Research Peptide

Research peptide · Lyophilized

BPC-157 Research Peptide

BPC-157 — USA Made, ≥99% Purity

4.9 177 verified reviews

USA manufactured in GMP-certified California and Arizona laboratory facilities
≥99% purity target with independent HPLC and mass spectrometry testing
10mg lyophilized vial backed by one combined, batch-specific COA

Vial Size

Manufactured in a GMP facility · Independently tested · Batch COA

Dispatched from a US warehouse within 48 hours, tracked

Certificate of analysis for lot BP-35677 below

Disclaimer

For research purposes only. Not intended for human consumption, medical use, diagnosis, treatment, or prevention of disease.

Specifications

Lot BP-35677

Purity target

≥99%

≥99% (3rd-Party HPLC Tested)

Molecular mass

1,419.5

g/mol, confirmed by mass spectrometry

Residues

Synthetic amino-acid chain

Sequence

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)

CAS: 137525-51-0
Molecular mass: 1,419.5 g/mol
Purity target: ≥99% (3rd-Party HPLC Tested)
Form: Lyophilized Powder
Origin: Manufactured, Formulated & Packaged in CA/AZ, USA
Storage: Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence associated with a gastric protein research program. Its short, defined structure has made it a widely discussed tool in laboratory models examining cellular signaling and tissue-response pathways.

Most published BPC-157 evidence comes from cell and animal studies. Researchers have investigated vascular signaling, cell migration, nitric-oxide regulation, and extracellular-matrix responses, but a single definitive receptor mechanism and robust human evidence remain limited.

How It Works

Engages vascular signaling in preclinical models: Studies have reported activity involving VEGFR2 and downstream Akt/eNOS signaling.

Influences cell movement and organization: FAK-paxillin and related pathways are being studied for their roles in cell adhesion and migration.

Modulates nitric-oxide balance: Experimental work suggests interaction with nitric-oxide systems, though the complete mechanism remains unresolved.

Analytical data

Every lot, on the record

Independent third-party HPLC evaluates the purity target, while mass spectrometry confirms molecular identity. Both results are documented in one combined, batch-specific Certificate of Analysis.

Purity (HPLC-UV)

99.46%

Net content

10.94 mg

Reported

2026-04-23

Identity (LC-MS): Confirmed
Appearance: White Lyophilized Powder

HPLC MS

Analyte	Method	Result
Identity	LC-MS	BPC-157
Purity	HPLC-UV	99.46%
Net Content		10.94 mg

Chromatogram

Mass confirmation

Download COA (PDF)

Why Source from 321 Peptides?

A domestic supply chain you can trace.

BPC-157 is synthesized and finished in GMP-certified laboratory facilities in California and Arizona. It is never sourced from overseas or Mexico.

Identity and purity are separate checks.

Third-party HPLC evaluates the ≥99% purity target, while mass spectrometry confirms that the expected peptide mass is present. One batch-specific COA reports both analyses.

Lyophilized for stability.

Freeze-dried powder helps protect this peptide from avoidable degradation during storage and transit. Domestic fulfillment keeps orders moving without an international shipping chain.

Lot history 4 released lots

Every batch released under this compound, with the figure reported for each.

Lot	Reported	Purity	Net content	COA
BP-79003 Superseded	2026-04-30	99.58%	10.01 mg	Pending
BP-80157 Superseded	2026-04-23	99.49%	10.03 mg	Pending
BP-35677	2026-04-23	99.46%	10.94 mg	PDF
BP-79580 Superseded	2026-02-25	99.83%	10.02 mg	Pending

Frequently Asked Questions

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide used in laboratory research on cellular, vascular, and tissue-response pathways. It is not an FDA-approved drug for human use.

How does BPC-157 work in research models?

Preclinical studies suggest BPC-157 can influence VEGFR2, Akt/eNOS, FAK-paxillin, and nitric-oxide signaling. Its full mechanism has not been conclusively established, and human evidence is limited.